Coiled coil interactions for the targeting of liposomes for nucleic acid delivery by Blenke, E.E.O. et al.
Nanoscale
PAPER
Cite this: Nanoscale, 2016, 8, 8955
Received 26th January 2016,
Accepted 20th March 2016
DOI: 10.1039/c6nr00711b
www.rsc.org/nanoscale
Coiled coil interactions for the targeting of
liposomes for nucleic acid delivery†
Erik E. Oude Blenke,a Joep van den Dikkenberg,a Bartjan van Kolck,b Alexander Krosb
and Enrico Mastrobattista*a
Coiled coil interactions are strong protein–protein interactions that are involved in many biological pro-
cesses, including intracellular traﬃcking and membrane fusion. A synthetic heterodimeric coiled-coil
forming peptide pair, known as E3 (EIAALEK)3 and K3 (KIAALKE)3 was used to functionalize liposomes
encapsulating a splice correcting oligonucleotide or siRNA. These peptide-functionalized vesicles are
highly stable in solution but start to cluster when vesicles modiﬁed with complementary peptides are
mixed together, demonstrating that the peptides quickly coil and crosslink the vesicles. When one of the
peptides was anchored to the cell membrane using a hydrophobic cholesterol anchor, vesicles functiona-
lized with the complementary peptide could be docked to these cells, whereas non-functionalized cells
did not show any vesicle tethering. Although the anchored peptides do not have a downstream signaling
pathway, microscopy pictures revealed that after four hours, the majority of the docked vesicles were
internalized by endocytosis. Finally, for the ﬁrst time, it was shown that the coiled coil assembly at the
interface between the vesicles and the cell membrane induces active uptake and leads to cytosolic deliv-
ery of the nucleic acid cargo. Both the siRNA and the splice correcting oligonucleotide were functionally
delivered, resulting respectively in the silencing or recovery of luciferase expression in the appropriate cell
lines. These results demonstrate that the docking to the cell by coiled coil interaction can induce active
uptake and achieve the successful intracellular delivery of otherwise membrane impermeable nucleic
acids in a highly speciﬁc manner.
Introduction
Coiled coil domains are structural motifs found in proteins of
2–7 α-helical strands that are coiled around each other.1–4 The
primary structure is typically composed of multiple heptad
repeat amino acid sequences (denoted as abcdefg) in which the
a and d residues are non-polar and create the hydrophobic
core of the coil. The e and g positions are charged residues
that introduce electrostatic interaction and specificity between
opposing coils.5 Coiled coil interactions are involved in many
biological processes, including intracellular traﬃcking and
membrane fusion, mainly mediated by SNARE proteins
(soluble N-ethylmaleimide-sensitive factor attachment protein
receptor).6,7
In nanomaterial research, synthetic coiled coil motifs have
been used to create a tunable system for the controlled display
of ligands on nanoparticles,8–10 defined architectures,11,12 and
for the self-assembly of polymer–peptide hybrid systems.13–17
The group of Kopeček used coiled coil peptides on a HPMA
polymer scaﬀold as a means to induce highly specific antigen
crosslinking on malignant B cells both in vitro and in vivo.18–21
These examples demonstrate the versatile application of
coiled-coils as surface modifications for molecular recognition
and their potential as signaling molecules on complex surfaces
such as the cell membrane.
In this study, the aim is to investigate the potential of syn-
thetic coiled coil peptides for liposomal drug delivery pur-
poses. To this end, two synthetic, parallel coiled coil forming
peptide sequences are used that are referred to as K3
(KIAALKE)3 and E3 (EIAALEK)3 (three repeats of lysine-rich
and glutamic acid-rich heptads). Originally they have been
designed as aﬃnity tags for recombinant protein purifi-
†Electronic supplementary information (ESI) available: Two videos of the experi-
ment are shown in Fig. 5, demonstrating the distinctive characteristics of the
peptide pair in a mixed population of cells are available in online. Video S1
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(calcein-AM stained unfunctionalized cells) and orange channel (rhodamine
labeled liposomes). Video S2 shows the exact same frames but combining the
fluorescent channels only, including the blue channel for Hoechst nuclear stain-
ing. Both videos consist of 31 frames at a frame rate of 5 fps. The labeled lipo-
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cation.22,23 Inspired by their natural role in membrane fusion,
coiled coil sequences have been previously used to mimic a
system where liposomal membranes fuse upon coiling of the
two complementary peptides.24–26 Recent work showed that
the peptide could be incorporated into a cellular membrane by
conjugating it to a hydrophobic moiety. Subsequently, lipo-
somes that were functionalized with the opposing coil could
be targeted to these cells, as was demonstrated for several cell
lines and zebra-fish embryos.27–29 In the present work we use
the K3/E3 combination to specifically dock stable nucleic acid
lipid particles to the target cell and achieve intracellular deliv-
ery. Nucleic acid drugs, like siRNA or splice correcting anti-
sense oligonucleotides (SCO) have the potential to modulate
disease pathways on the transcriptional level, but due to their
large size and negatively charged backbone they cannot reach
their intracellular site of action. Therefore they require a deliv-
ery vehicle such as the liposomes used here. Liposomes are
lipid vesicles that protect the oligonucleotides from degra-
dation and can help to deliver them to their intracellular
target site, but they do require further surface modification to
get access to the target cell. In the work presented here, the
lipid vesicles were functionalized with either K3 or E3 coil pep-
tides and the cell surface was modified by insertion of the
complementary peptide using a hydrophobic anchor. The
assembly of the K3/E3 coiled coils at the cell surface was
shown to initiate endocytosis and to eventually achieve the
functional delivery of two types of membrane impenetrable
oligonucleotides. This poses a novel alternative to viral carriers
or lipid/polymer based transfection reagents that are either
associated with toxicity/immunogenicity, or are highly unspeci-
fic. Live cell confocal imaging was used to monitor peptide-
specific docking over time and revealed that this happens in a
very short timeframe and with a very high distinctive character,
demonstrating the high aﬃnity and specificity of the used
peptide pair.
Experimental section
Materials
Dioleoylphosphatidylethanolamine (DOPE), 1,2-dioleoyl-3-di-
methylammonium-propane (DODAP), N-palmitoyl-sphingo-
sine-1-succinyl[methoxy(polyethylene glycol)2000] (C16
Ceramide-PEG2000), 1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine-N-[maleimide(polyethylene glycol)-2000]
(DSPE-PEG2000-maleimide), and L-α-phosphatidylethanola-
mine-N-(Lissamine Rhodamine B sulfonyl) (Rho-PE) were from
Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol was from
Sigma-Aldrich (St. Louis, MO, USA).
The siRNA sequences directed against luciferase are as
follows: sense 5′- AC̲G GAGU̲A GAdTdT-3′; anti-
sense 5′-UCGAAGUACUCAGCGUAAGdTdT-3′. Antisense oligo-
nucleotide Luc705 is made of all phosphorothioate bases
5′- -3′ (underlined bases are 2′-O-
methyl modified). All oligonucleotides were provided by Glaxo-
SmithKline (Stevenage, UK) for use within the EU IMI
COMPACT consortium. Cysteine modified K3 and E3 peptides
(Ac-CKIAALKEKIAALKEKIAALKE-NH2 and Ac-CEIAALEKEI-
AALEKEIAALEK-NH2) were ordered in >90% purity from Gen-
script Corp. (Piscataway, NJ, USA). Lipidated peptides
cholesterol-PEG12-K3 and cholesterol-PEG12-E3 (CPK and CPE)
were synthesized as described before.25
Liposome preparation
Stable nucleic acid–lipid particles are prepared using the pre-
formed vesicle method of Maurer et al.30 using a lipid compo-
sition of DODAP/DOPE/cholesterol/C16 Ceramide-PEG2000 at
a ratio of 26/22/46/6.
For labeled vesicles, 0.5% Lissamine Rhodamine-PE was
included. Using a rotary evaporator, a dry lipid film of 40 μmol
total lipid was created in a round bottom flask. After flushing
with nitrogen, the lipid film was hydrated in 70% citrate buﬀer
50 mM pH 4.0 and 30% ethanol to a lipid concentration of
8 mM. The hydrated lipids were extruded through 100 nm
pore-sized filters (Nuclepore, Pleasanton, CA, USA) using a
Lipex™ Extruder (Northern Lipids, Burnaby, BC, Canada) for
10–12 times. Nucleic acids (NA) (splice correcting oligo or
siRNA) were dissolved in 70% citrate buﬀer 50 mM pH 4.0 and
30% ethanol. Both the vesicles and the NA solution were pre-
heated to 37 °C and then mixed together under continuous
heavy stirring in a final NA/lipid ratio of 0.06 (wt/wt). The
mixture was then incubated for 1 hour at 37 °C to allow re-
organization of the vesicles. Ethanol was removed and the
buﬀer was replaced by overnight dialysis in a 10 K MWCO Slide-
A-Lyzer G2 Dialysis Cassette (Life Technologies) at 4 °C against
PBS. Unloaded vesicles were dialyzed directly after extrusion.
After dialysis, loaded vesicles were subjected to three rounds of
ultracentrifugation in a Type 70.1 Ti rotor for 50 minutes at
55 000 rpm at 4 °C to wash away unencapsulated NA.
Insertion of K3- and E3-peptides into the formulated vesicles
To reduce the C-terminal cysteine thiol groups, K3 and E3 pep-
tides were incubated with Immobilized TCEP Disulfide Reduc-
ing Gel (Pierce #77712) for 1 hour at room temperature and
then separated from TCEP gel slurry by centrifugation in paper
filter spin cups (Pierce #69700). Immediately afterwards they
are added to DSPE-PEG2000-maleimide micelles, dispersed in
PBS pH 7.4, in a 1 : 1 molar ratio of thiol : maleimide and incu-
bated overnight at 4 °C. For insertion of the peptide micelles
into the vesicles,31 the vesicles and the micelles are preheated
to 45 °C. The K3 or E3 micelles were then added to the vesicles
in a 1 : 100 molar ratio and incubated overnight at 45 °C
(extrapolated from the total amount of phospholipids,
measured as described below). To remove the uninserted
micelles, the resulting vesicles were subjected to three rounds
of ultracentrifugation in a Type 70.1 Ti rotor for 50 minutes at
55 000 rpm at 4 °C.
Characterization of vesicles
To separate the lipids from the NA, samples are extracted
according to Bligh and Dyer.32 The top phase of the extraction
was collected and evaporated using a centrifugal concentrator.
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When completely dry, the samples were reconstituted in
MilliQ water and the amount of nucleic acid was measured by
UV/VIS spectrophotometry at 260 nm using a NanoDrop 1000
spectrophotometer (Thermo Scientific). The lipid fraction in
chloroform was assayed for the total phosphate amount
according to the method of Rouser using sodium biphosphate
as a standard.33 The total lipid amount was then extrapolated
from the amount of phospholipid (DOPE) present in the for-
mulation. The encapsulation eﬃciency was calculated using
the formula
Encapsulation efficiency %ð Þ
¼
oligonucleotides½ 
phospholipids½  after ultracentrifugation
oligonucleotides½ 
phospholipids½  before dialysis
 100
The hydrodynamic diameter and the polydispersity index
were measured by dynamic light scattering, using a Malvern
CGS-3 multiangle goniometer with a He–Ne laser source (λ =
632.8 nm, 22 mW output power) under an angle of 90°
(Malvern Instruments, Malvern, UK). The zeta-potential of the
liposomes was measured using laser Doppler electrophoresis
on a Zetasizer Nano-Z (Malvern Instruments) with samples dis-
persed in 10 mM Hepes buﬀer pH 7.4 (no additional salts).
Aggregation assay
To demonstrate that the peptides are freely accessible on the
distal end of the inserted PEG-lipids, the peptide mediated
aggregation of the vesicles is measured by dynamic light scat-
tering as described above. The vesicles were diluted to 25 nM
phospholipid in PBS and the hydrodynamic diameter was
measured every minute for a total of 25 minutes. K3- and E3-
functionalized vesicles were mixed together and immediately
afterwards the measurement was started. K3- and E3-functio-
nalized vesicles were mixed with unfunctionalized vesicles as
controls.
Cell culture
For antisense oligo delivery, HeLa cells expressing the luci-
ferase gene interrupted by mutated human β-globin intron 2
(IVS2-705) (HeLa pLuc705) were used.34 For siRNA delivery
HeLa cells stably transfected with a EGFPLuciferase gene
under the PGK-promoter were used (construct described
here35). All cells were cultured in Dulbecco’s Modified Eagle’s
Medium with high glucose supplemented with 10% (v/v) fetal
bovine serum and penicillin–streptomycin–amphotericin B at
37 °C under a humidified atmosphere containing 5% CO2. The
medium for the HeLa pLuc705 cell line also contained 200 μg
ml−1 of hygromycin B. All media and supplements were from
Sigma-Aldrich. Cells were regularly tested for mycoplasma and
all cell lines used were found to be negative.
Microscopy
10 000 HeLa pLuc705 cells were seeded per channel of an Ibidi
µ-Slide VI0.4 (Ibidi GmbH, Munich, Germany) one day prior to
the addition of the vesicles. On the day of the experiment, cells
were washed with PBS once and incubated with 5 μM CPE or
CPK in OptiMEM medium without phenol red (Life Techno-
logies) for 5 minutes at 37 °C. As a control OptiMEM medium
without the peptides was used. Cells were washed with PBS
and incubated with rhodamine labeled vesicles (125 μM phos-
pholipid) in OptiMEM for 10 minutes at 37 °C. Cells were
washed with PBS and incubated in OptiMEM containing
1 μg ml−1 Hoechst 33342 (Life Technologies, Bleiswijk, Nether-
lands) and incubated for 15 minutes at 37 °C. Cells were
washed with PBS and immediately imaged in OptiMEM on a
Keyence BZ-9000 fluorescence microscope (Keyence, Düssel-
dorf, Germany) using a Nikon CFI Plan APO VC 60× oil immer-
sion lens (NA 1.4 WD 0.13). Overlay pictures were made in
BZ-II Analyzer software (Keyence). For uptake studies, cells
were incubated on separate slides at 37 °C for an additional
1 or 4 hours and then washed and imaged. No nuclear staining
was applied in these studies.
To test the distinctive character of the peptide pair, 10 000
HeLa pLuc705 cells were seeded in a µView clear-bottom 96
well plate (Greiner Bio-One B.V. Alphen aan de Rijn, Nether-
lands). Next day, nuclei were stained as described above and
after aspiration of the medium, the middle of the well was
blocked with a piece of Teflon (PTFE) tube, with an outer dia-
meter of 3 mm. The area outside the tube was incubated with
CPE as above and after washing, the ring barrier was removed
and the whole well was incubated with rhodamine labeled
K-functionalized vesicles (125 μM phospholipid). After
washing, the cells were incubated in OptiMEM and imaged in
a Yokogawa Cell Voyager 7000 (Yokogawa, Tokyo, Japan) (see
the inset in Fig. 4 for a schematic view).
A similar experiment was performed with cells in suspen-
sion. For this cells were stained with Hoechst as described
above and then split in separate vials. These were incubated
separately with CPE or OptiMEM with 250 nM of calcein-AM
(Life Technologies) for 5 minutes at 37 °C. In between incu-
bation steps cells were washed with PBS using centrifugation
at 250g for 3 minutes. After this the two vials were combined
and 10 000 cells were then transferred to a µView clear-bottom
96 well plate and imaged while still in suspension in the Cell
Voyager. An equal volume of K3-functionalized rhodamine-
labeled vesicles (final concentration of 125 µM total lipid) was
injected 30 seconds after the onset of the live cell imaging
using a built-in dispenser. A picture was taken every
30 seconds over a time period of 15 minutes. These pictures
were converted into a time-lapse movie with 5 frames per
second. See ESI Videos 1 and 2.†
Transfection studies
Transfection studies were done in 24 well plates, with HeLa
pLuc705 cells seeded at a density of 45 000 cells per well and
HeLa PGK-EGFPLuciferase cells at a density of 35 000 cells per
well 24 h before transfections. On the day of the experiment,
cells were washed once with PBS and half of the wells were
incubated with 5 μM CPE or CPK in OptiMEM and the other
half with plain OptiMEM for 5 minutes at 37 °C. Cells were
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washed with PBS and incubated with SCO or siRNA loaded
vesicles (1 μM oligonucleotides) in OptiMEM for 4 hours at
37 °C. Afterwards, transfection mixtures were replaced by the
complete medium and plates were incubated for 24 hours at
37 °C. As a positive control for nucleic acid delivery, Lipofecta-
mine 2000 (Life Technologies) was used according to the
manufacturer’s protocol. Each condition was measured in
triplo. The following day, cells were washed once with PBS and
lysed with 250 μl of lysis buﬀer (Tris 25 mM, EDTA 2 mM, 1%
Triton X-100, 10% glycerol) on a shaking board at 37 °C for
10 minutes. For each well, 50 μl of lysate was mixed with 50 μl
of Luciferase Assay Reagent (Promega, Leiden, Netherlands) in
triplo. The reagent was injected using a FLUOstar OPTIMA
microplate reader (BMG Labtech, Ortenberg, Germany)
equipped with an injection pump. 2 seconds after injection,
luminescence was measured for 10 seconds according to the
supplier’s recommendation. Results are plotted as mean plus
standard deviation in GraphPad Prism 6. Statistical analysis
was performed using multiple paired t-tests. Statistical signifi-
cance is denoted as *** with p < 0.001.
Results
Formulation of stable nucleic acid vesicles with high loading
The stable nucleic acid lipid particles used here were prepared
by the preformed vesicle method.30 In this procedure, ethanol
is used to destabilize the preformed empty unilamellar vesicles
which enables entrapment of the nucleic acids. The vesicles
used here consist of DOPE/DODAP/cholesterol/C16 Ceramide-
PEG2000 at a molar ratio of 22/26/46/6. DODAP is a lipid with
a positive charge at pH of formulation which is necessary for
interaction with the nucleic acids and with the predominantly
negatively charged cell membrane.30,36 DOPE is a so called
‘helper lipid’, that prefers to adopt the inverted hexagonal (HII)
phase which favors intracellular delivery.36 A PEG-lipid with
the Ceramide C16 anchor was used, because it is known to dis-
sociate from the bilayer.37 The diameter of unfunctionalized
vesicles is ∼80 nm and their zeta potential is almost neutral
due to the PEG-lipids (Table 1).
Two types of nucleic acids were encapsulated in two separ-
ate batches of liposomes, a double stranded siRNA against
luciferase and a single stranded splice correcting oligo-
nucleotide (SCO) that corrects the splicing of luciferase pre-
mRNA in the HeLa pLuc705 cell line.34 The nucleic acids that
were not encapsulated were removed from the vesicles by ultra-
centrifugation and the encapsulation eﬃciency was calculated,
and corrected for the total amount of phospholipids. The
encapsulation eﬃciencies for both types of nucleic acids are
generally high, with values around 90% encapsulation on
average which is typical for this preparation method30
(Table 2).
Insertion of the coiled coil forming peptides into the lipid
vesicles
The formulated liposomes were functionalized with the coiled
coil forming peptides K3 C(KIAALKE)3 and E3 C(EIAALEK)3.
The peptides are covalently coupled to a DSPE-PEG2000-malei-
mide lipid via a thioether bond, on the N-terminal cysteine
(see Fig. 1). The formed peptide micelles are then inserted
into the vesicles using the ‘post-insertion method’.31 These
vesicles are functionalized with 1% of the total lipids in the
outer layer by being coupled to a peptide. The insertion of the
peptides is reflected by an increase in hydrodynamic diameter
to ∼100 nm and a small change in the zeta potential (Table 1).
Rapid clustering and aggregation of complementary
functionalized vesicles
To demonstrate that the conjugated peptides are functional
and accessible, the size increase and aggregation were moni-
tored when the two populations of vesicles were mixed
together. The two individual populations were stable when
stored, but when mixed together, they quickly agglomerated
into bigger clusters. An increase in turbidity was observed by
the eye. Dynamic light scattering measurements over time
showed a gradual increase in the particle size (Fig. 2A).
Immediately after mixing, particle size increased, which is in
line with the high association constant of the coiled coil pair.
The increase in size appeared to be bigger over time, which is
explained by the exponential eﬀect of larger particles cluster-
ing together. No size increase was seen when either of the
populations were mixed together with unfunctionalized vesi-
cles, excluding the possibility that clustering is caused by one
of the peptides inserting into the membrane of other vesicles
(Fig. 2B). The degree of size increase is concentration depen-
dent with lower concentrations showing less or no size
increase at all, while higher concentrations are more proble-
matic to measure due to obscuration of the laser (data not
shown). This is in line with the previous experiments where
full length SNARE-driven vesicle fusion was studied showing
that docking of the complementary SNAREs (and not fusion) is
the rate-limiting step.38 In other words, the collision and
docking of two vesicles is the bottleneck in the process, which
directly correlates with vesicle concentration.26 This also
explains why the fusion or aggregation rate of these artificial
Table 2 Encapsulation eﬃciencies for the diﬀerent types of nucleic
acids (averages and standard deviation of three diﬀerent formulations)
Nucleic acid Encapsulation eﬃciency
siRNA 92.4% ± 4.2%
SCO 87.1% ± 5.4%
Table 1 Basic characteristics of the unloaded vesicles (averages and
standard deviation of three measurements)
Sample Size PDI Zeta potential
Unfunctionalized vesicles 83.6 ± 0.6 0.06 −3.4 ± 0.3
E3-functionalized vesicles 97.4 ± 1.3 0.08 −7.7 ± 0.6
K3-functionalized vesicles 96.6 ± 0.7 0.07 −7.2 ± 0.7
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systems is much slower (timeframes of minutes or hours, rather
than (milli)seconds) than that of physiological fusion where
tethering proteins facilitate the earliest vesicle contact.6,7
Docking of the functionalized vesicles to the cell membrane
Next, it was tested whether the vesicles could also be docked to
live cells using the K3/E3 coiled coil interaction. In earlier
work, it was shown that using a hydrophobic anchor, both
peptides could be inserted into existing membranes, either
liposomal25 or the membranes of living cells.27 In the present
work, the membranes of live HeLa pLuc705 cells were functio-
nalized with a cholesterol anchored peptide on a short PEG
spacer (cholesterol-PEG12-peptide, abbreviated as CPK and
CPE, see Fig. 1). After washing, the cells were incubated with
liposomes labeled with 0.5 mol% rhodamine-PE, functiona-
lized with either the K3 or E3 peptide and then imaged using
an epifluorescence microscope. Strikingly, it was found that
K3-functionalized liposomes docked to E3-functionalized cells,
but not the other way around (Fig. 3).
This is in contrast with previous work that showed that
both the CPE and the CPK lipopeptide could be inserted into
the cellular membrane when CHO cells were used.27 It should
be noted that it is experimentally diﬃcult to study whether the
lipopeptide has indeed been inserted into the membrane via
its hydrophobic anchor. However, the absence of a fluo-
rescence signal when untreated cells are incubated with the
K3-functionalized vesicles strongly indicates that the signal is
dependent on the CPE peptide. Additionally, when CPE-incu-
bated cells were incubated with E3-functionalized vesicles no
fluorescence was observed, showing that the signal is depen-
dent on heterodimeric coiled-coil formation between the K3
and E3 peptides (Fig. 3D).
Fig. 1 Peptide sequences and anchors used. Peptides were coupled via maleimide–thiol linkage to a lipid (top) or were directly conjugated to the
cholesterol anchor (bottom). The lipid anchored peptides were inserted into the liposomes and the cholesterol anchored peptides were used to
functionalize the cell membranes.
Fig. 2 Increase in the hydrodynamic diameter of the mixed vesicles over time. Individual populations were stable in size but when the E3- and K3-
functionalized vesicles were mixed together, a quick increase in size was observed.
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Similar to our results, Yano et al. found that when the K3
and E3 peptides were recombinantly fused to a membrane
protein, only when the E3 variant was expressed, it could be
fluorescently tagged by the complementary K4 peptide.39 It is
known that these peptides interact diﬀerently with membranes
and it is likely that these interactions are also cell type depen-
dent. The interactions of the lipidated K3 and E3 peptides
with a model membrane were previously studied using surface
sensitive infrared reflection absorption spectroscopy (IRRAS)
and circular dichroism (CD) spectroscopy. These studies
showed that peptide E3 has no interaction with the membrane
whereas the K3 peptide has a much higher binding aﬃnity for
the membrane amphiphiles.40,41 This is explained by the so-
called snorkeling eﬀect of K3 similar to class A peptide amphi-
philes. Also, the net charge of the E3 and K3 peptides, which
is −3 and +3 respectively, while the cellular membrane has a
net negative charge, plays a role. Applying this knowledge to
our findings, it is expected that the CPE lipopeptide is not hin-
dered by charge interaction with the membrane, allowing it to
insert into the membrane with its hydrophobic anchor. The
CPK lipopeptide is more likely to stick to the negatively
charged glycolipids on the surface of the cell membrane, pre-
venting insertion of the cholesterol anchor with the appropriate
orientation. The peptide is then either washed away or the
membrane interactions prevent it from dimerization with the
complementary peptide. The microscopy images show that the
interaction of the K3-functionalized vesicles with the untreated
cell membrane is not strong enough to bind the liposomes to
the cell membrane after the washing steps, as evidenced by the
lack of a fluorescence signal (see Fig. 3B and C). Only the coiled
coil interaction of the CPE and K3-functionalized vesicles is
strong enough to unequivocally label the membrane, again
exemplifying the strong interaction between the peptide pair.
Distinctive character of the peptide pair in a mixed population
of cells
To test the selectivity of the K3-functionalized vesicles towards
cells bearing the complementary peptide, a mixture of CPE-
functionalized and unfunctionalized cells was incubated with
K3-functionalized vesicles. In this experiment, a part of the
cells in a 96 well plate was blocked with a Teflon tube and the
area around it was functionalized with CPE. Cells were then
Fig. 3 (A–I) Microscopy pictures of HeLa pLuc705 cells incubated with rhodamine-labeled vesicles. Overlay of the red and blue channels is shown
for all combinations but only when CPE functionalized cells were incubated with K3-functionalized vesicles, cell binding was seen in the red
channel. Nuclei were stained with Hoechst 33342 dye in the blue channel.
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washed and after the barrier was removed, they were incubated
with labeled K3-functionalized vesicles. When pictures were
taken using a microscope there was a very clear diﬀerence in
liposome binding between the CPE-functionalized cells and
the unfunctionalized cells (Fig. 4). The round shape of the
barrier could easily be recognized in the binding pattern indi-
cating no diﬀusion or cross-over of the anchor and no oﬀ-
target binding of the liposomes.
Because there may be more diﬀusion and cross-over in solu-
tion, a complementary experiment was performed with cells in
suspension. HeLa pLuc705 cells were counted and then split,
after which half of them were incubated with CPE and the
other half with a control medium containing calcein-AM to
distinguish between the two populations, also before incu-
bation with the vesicles. After washing, the cells were pooled
in a one to one ratio and incubated with K3-functionalized
vesicles. After another washing step, the cells were imaged
under the microscope in suspension (Fig. 5).
Also in suspension, two diﬀerent populations could be
distinguished. The green labeled unfunctionalized cells did
not show any interaction with the vesicles whereas the func-
tionalized cells were clearly labeled red. The red labeled
cells cluster more than the unfunctionalized cells, which
could indicate that there is some homo-coiling of the CPE
peptides in the functionalized cells, or that the K3-functio-
nalized vesicles are crosslinking the cells, similar to as was
seen in the aggregation assay with K3- and E3-functionalized
vesicles (Fig. 2). When monitoring over a timeframe of
15 minutes, it was seen that membrane labeling starts
immediately after addition of the labeled liposomes. A video
of the increasing red fluorescence over time is available in
the ESI (Videos S1 and S2†).
Fig. 4 Adherent CPE-functionalized and unfunctionalized HeLa pLuc705 cells incubated with rhodamine-labeled K3-functionalized vesicles. After
seeding, part of the well (96 well plate) was blocked using a Teﬂon ring. Outside this barrier, cells were incubated with CPE. After washing, the
barrier was removed and the entire well was incubated with rhodamine-labeled K3-functionalized vesicles (inset). Overlays with the brightﬁeld
picture (left) and with the Hoechst nuclear staining (right) show that the CPE-functionalized cells were labeled red and the outer rim of the area
where the barrier was positioned was clearly visible.
Fig. 5 Mixed population of CPE-functionalized and unfunctionalized HeLa pLuc705 cells incubated with rhodamine-labeled K3-functionalized
vesicles in suspension. Unfunctionalized cells were incubated with calcein-AM to distinguish between the two populations. Overlays with the
brightﬁeld picture (left) and with the Hoechst nuclear staining (right) show that the CPE-functionalized cells were clearly labeled red while the other
population that was not functionalized had no detectable interaction with the vesicles at all.
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The cells in these experiments had the exact same back-
ground and thus membrane proteins and receptors, with the
CPE peptide as the only diﬀerence. The ability to distinguish
between these two cell populations both in adherent cells and
in suspension demonstrates the high specificity of the peptide
pair. This allows for new possibilities to selectively target cells
in the same vessel, regardless of any existing cell surface
properties.
Functional delivery of nucleic acid payloads after docking
When docking was successfully demonstrated, it was tested
whether these vesicles and the coiled coil interaction could be
used to functionally deliver model nucleic acid payloads. For
delivery of the single stranded oligonucleotide (SCO), the HeLa
pLuc705 cell line was used. This cell line is stably transfected
with a luciferase gene that is interrupted by a mutated human
β-globin intron 2 (IVS2-705), described by Kang et al.34 Under
normal conditions, this results in the encounter of a pre-
mature stop codon and the expression of a truncated, non-
functional luciferase protein. When the 705 exon skipping
SCO is successfully delivered, the splicing site (at position 705)
is masked and the unnatural exon is spliced out, resulting in
the restoration of luciferase expression.34 For the delivery of
conventional siRNA, a HeLa cell line stably expressing a luci-
ferase construct was used.35 Similar to the microscopy experi-
ments, the cells were incubated with the CPE or CPK
lipopeptide but then followed by incubation with SCO or
siRNA loaded liposomes, functionalized with K3, E3 or
unfunctionalized. After the transfection experiments, cells
were lysed and luciferase expression was measured.
Successful transfection and restoration of luciferase
expression were demonstrated when the HeLa pLuc705 cells
were modified with CPE and the SCO loaded vesicles were
functionalized with the K3-peptide. K3-functionalized vesicles
did not transfect the unfunctionalized cells. When compared
to the positive control Lipofectamine 2000, the eﬃciency of
exon-skipping is approximately 60%. Unfunctionalized vesicles
did not deliver the nucleic acid cargo and neither did the E3-
functionalized vesicles to the CPK modified cells (Fig. 6). This
was also seen in the docking experiment and this again shows
that the eﬀect is dependent on coiled coil formation of the
complementary peptides. The same peptide dependency is
seen when siRNA is delivered to the HeLa PGK-Luciferase
cells, however, the silencing eﬀect when compared to lipofecta-
mine was only 25% (Fig. 7).
What is of more importance is the mechanism by which
these vesicles deliver the nucleic acids. Clearly, the docking of
the peptides is important, since unfunctionalized vesicles do
not transfect. A logical explanation would be that docking of
vesicles at the cell membrane triggers a direct fusion mechan-
ism with the cell membrane, thereby delivering the splice cor-
recting oligonucleotide. The fusion of natural membranes is
initiated by SNARE proteins that pull the opposing membranes
in juxtaposition.6,7 That could also be the mechanism of deliv-
ery for the vesicles in the present work, but herein, the pep-
tides are on the distal end of a PEG polymer (MW ∼ 2000,
PEG45) so the two membranes are in fact not that close. In the
work of Pähler et al., the eﬀect of parallel versus anti-parallel
docking of the E3/K3 pair on synthetic vesicles was investi-
gated.42 Half of the peptides were synthesized in the reverse
order, such that when the peptides assembled, the N- and
C-termini were together (anti-parallel docking) as opposed to
the two N-termini in the normal situation (parallel docking). It
was found that the anti-parallel coil assembly only resulted in
docking while the parallel orientation also led to fusion
(defined as the exchange of lipids and aqueous content
between the diﬀerent vesicle populations).42 This was
explained by the increased distance between the bilayers when
Fig. 6 Luciferase expression in HeLa pLuc705 cells after transfections with SCO loaded vesicles. Baseline expression was low and was restored after
successful transfection. Grey bars represent CPE modiﬁed cells (left) and CPK modiﬁed cells (right). Black bars represent unfunctionalized cells
(*** denotes p < 0.001).
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the peptides dock anti-parallel and in that work, the peptides
were conjugated directly to the bilayer, without any additional
PEG spacer like in our work. Therefore, with our PEGylated
vesicles, it is not likely that the membranes are brought in
direct contact immediately after docking.
To investigate the delivery mechanism, microscopy images
of the labeled vesicles, docked to the cells were taken over time
to monitor cellular uptake. When the cells are imaged directly
after incubation, a very clear, homogeneously distributed
membrane labeling is seen (Fig. 8).
After one hour, the membrane labeling is less clear and
bright red spots appear, indicating that the vesicles are in fact
taken up in endosomal compartments. After four hours of
incubation, which corresponds with the incubation time in
transfection studies, the membrane labeling becomes much
less intense, while the endosomal spots become much more
prominent and numerous. These pictures show that despite
the absence of a downstream signaling cascade, the vesicles
are actively taken up, possibly by non-specific uptake mecha-
nisms such as macropinocytosis or membrane recycling
mechanisms.
Discussion and conclusion
The results presented here show that the highly distinctive
interaction between the K3- and E3-peptides and more specifi-
cally, the interaction between K3-functionalized vesicles and
CPE-functionalized cells, can lead to the functional delivery of
two types of small oligonucleotides that normally do not cross
the cellular membrane. It was demonstrated that merely the
docking to the cell membrane and the coiling of the peptide
Fig. 7 Luciferase silencing in HeLa PGK-Luciferase cells after transfections with siRNA loaded vesicles. Baseline expression is high and is silenced
after successful transfection. Grey bars represent CPE modiﬁed cells (left) and CPK modiﬁed cells (right). Black bars represent unfunctionalized cells
(*** denotes p < 0.001).
Fig. 8 Microscopy pictures of CPE-functionalized HeLa pLuc705 cells incubated with K3-functionalized rhodamine-labeled vesicles over time.
Directly after adding the vesicles, the cell membrane is clearly and homogeneously labeled. After one hour of incubation, brightly colored compart-
ments start to appear. After four hours, the membrane labeling almost disappears and more numerous and brighter compartments are now visible,
indicating an active uptake of the vesicles over time.
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pair at the cell surface, leads to uptake in endocytic vesicles
and eventually to cytosolic delivery. Furthermore, this inter-
action is specific enough to distinguish between cells of an
identical background in the same vial that were or were not
functionalized with the complementary peptide. This discrimi-
nation is independent of any existing surface protein
expression and allows for highly specific cell binding and
recognition.
Alternative to our approach of inserting the CPE lipopeptide
into the cell membrane, the peptide could be recombinantly
expressed to tag specific cell subsets and to obtain a highly tar-
geted docking of liposomes to their cell membranes required
as a first step towards the targeted delivery of nucleic acids.39
For an in vivo application however, this would require another
transfection with another targeted vector in order to get this
artificial construct expressed on the target cell first. A more
viable two-step approach was described by the group of
Kopeček, where one of the coil forming peptides was fused to
a Fab’ fragment and in this way docked on the target cells
in vitro and in vivo. A polymer functionalized with the com-
plementary peptide could then interact with its target cell
through an assembly of the peptides.18,19 This approach was
also shown to be feasible in vivo and could be combined with
imaging applications.20,21 Another in vivo application is
inspired by the very interesting work by Raemdonck et al. in
which “hitchhiking nanoparticles” are described.43 In that
work, lipid nanoparticles were reversibly coupled to isolated
cytotoxic T-lymphocytes that are known to migrate to the
tumor upon re-administration to the body. In this way, the
concentration of nanoparticles in the tumor is increased. The
cholesterol lipopeptide could be an alternative way to functio-
nalize the lymphocytes ex vivo and the very high aﬃnity and
specificity of the peptide pair that was demonstrated in the
present work, could aid the nanoparticles in hitchhiking to
the tumor area.
Expanding on this, there are many other applications where
cells are manipulated ex vivo that could benefit from a highly
specific non-viral gene delivery system to modify the cells of
interest. For example, T-cells can be re-directed by transferring
T-cell receptor genes, or by transducing them with chimeric
antigen receptors.44 Another important example is the gene
editing system CRISPR/Cas9 which at this point also appears
to have more ex vivo applications than in vivo use due to the
current high oﬀ-target mutagenesis.45 So far it has been used
to inactivate latent HIV-infections in primary T-cells46 and to
correct the dystrophin gene in Duchenne’s Muscular Dystro-
phy patient-derived induced pluripotent stem cells.47,48
To summarize, there is a growing interest in the ex vivo
manipulation of cells, both on the cell surface as well as at the
genomic level, to use them as a targeted delivery system. These
applications can benefit from a highly selective, non-viral
delivery system that is capable of functionally delivering
nucleic acid cargos. This work shows the proof of concept that
such molecules can be delivered using an artificial coiled coil
forming targeting system that is independent of any existing
cell surface properties or genetic background.
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